Ranbaxy gets approval to market Ran-Rosuvastatin drug in Canada
Mumbai: Indian generic drug maker Ranbaxy Laboratories Ltd. said Saturday that its subsidiary in Canada got an approval from Health Canada to manufacture and market Ran-Rosuvastatin tablets, a cholesterol-lowering medication, to the Canadian healthcare system.
Ranbaxy said the approval for this molecule will provide an affordable alternative to the brand Crestor in Canada, which had sales of USD 742.2 million in 2011.
"We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, president and general manager of Ranbaxy Pharmaceuticals Canada Inc., the subsidiary of Ranbaxy Laboratories.
The finished dosage form will be manufactured within Ranbaxy Laboratories's Health Canada approved facilities located in India, said Drake.